Early Diagnosis of Rheumatoid Arthritis Crucial
Synopsis: Delay in assessment by rheumatologist increases risk of joint destruction, decreases remission chances.1
Main DigestEarly diagnosis of rheumatoid arthritis crucial to positive outcomes for patients - Delay in assessment by rheumatologist increases risk of joint destruction, decreases remission chances.
Positive outcomes in rheumatoid arthritis (RA) are closely linked to early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs). A study by researchers in the Netherlands found that patients who are assessed by rheumatologists soon after RA symptoms appear are more likely to experience less joint destruction and improved chances of DMARD-free disease remission. Details of this novel study are published in the December issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.
The World Health Organization (WHO) estimates that RA affects up to 1% of the population worldwide and is associated with increased morbidity, mortality, and healthcare costs. This chronic, systemic disease is characterized by inflammation in the lining of the joints which can frequently lead to joint damage. Current medical evidence suggests that early initiation of an optimal RA treatment strategy within 12 weeks of symptom onset can prevent joint damage, improve long-term function, and increase the likelihood of achieving disease remission.
Dr. Michael van der Linden and colleagues from the Leiden University Medical Center examined 1674 early arthritis patients from the Leiden Early Arthritis Clinic cohort. Of those participants, 598 (36%) were RA patients who were diagnosed between 1993 and 2006. Researchers studied the associations among total delay to physician assessment, achievement of DMARD-free-remission, and the rate of joint damage over a six-year follow-up period. Total delay was calculated as the sum of "patient delay" (time from symptom onset until patient seeks and is assessed by a general practitioner (GP)) and "GP delay" (time lapse between seeing the GP and a referral to- and appointment with a rheumatologist).
Results showed the median patient, GP, and total delay in evaluation of early arthritis patients were 2.4, 8.0, and 13.7 weeks, respectively. "Early treatment intervention dramatically improves clinical outcomes in patients with RA," said Dr. van der Linden. "Our study presents the first evidence that RA patients who have a delay longer than 12 weeks between first symptoms and visiting a rheumatologist have a higher rate of joint destruction and lower chance of achieving a sustained DMARD-free remission." In 69% of RA patients, an examination by a rheumatologist took place 12 or more weeks after symptoms began, which researchers suggest contributed to a joint destruction rate that was 1.3 times higher than patients assessed prior to 12 weeks. A delay in treatment was also associated with greater risk (1.87 hazard ratio) of not achieving DMARD-free disease remission.
In a related editorial published in this month's issue, Dr. Paul Emery, Arthritis Research UK Professor of Rheumatology and Head of Musculoskeletal Diseases at Chapel Allerton Hospital in the United Kingdom and Dr. Vivian Bykerk from Brigham and Women's Hospital in Boston, Massachusetts point out that previous studies showed delays to care are frequent, but the study by van der Linden et al. was the first to actually document the negative impact of delayed RA treatment. "These data provide further evidence that rheumatologists have the greatest impact on patients with RA when they intervene early in the disease course," commented Dr. Emery. He further noted strategies that may help reduce delays in care such as pre-screening referrals, an introduction of a specialized rheumatology referral form for GPs to use that identify urgent referrals, or set-up of central triage clinics.
Dr. van der Linden concluded, "Our results highlight the importance of reducing the delay in assessment by a rheumatologist and further studies could test whether accelerated treatment leads to improved disease outcomes in RA." The ACR and European League Against Rheumatism (EULAR) have set up a task force to address the issue of improving RA patient outcomes through early intervention.
These studies are published in Arthritis & Rheumatism. Media wishing to receive a PDF of the articles may contact firstname.lastname@example.org.
Article: "Long-term Impact of Delay in Assessment of Early Arthritis Patients." Michael P.M. van der Linden, Saskia le Cessie, Karim Raza, Diane van der Woude, Rachel Knevel, Tom W.J. Huizinga, Annette H.M. van der Helm-van Mil. Arthritis & Rheumatism; Published Online: August 18, 2010 (DOI: 10.1002/art.27692); Print Issue Date: December 2010. onlinelibrary.wiley.com/doi/10.1002/art.27692/abstract.
Editorial: "Long-Term Impact of Delay to Rheumatology Care in Patients with Early Arthritis." Vivian Bykerk and Paul Emery. Arthritis & Rheumatism; Published Online: August 18, 2010 (DOI: 10.1002/art.27691); Print Issue Date: December 2010. onlinelibrary.wiley.com/doi/10.1002/art.27691/abstract.
About the Journal -Arthritis & Rheumatism is an official journal of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP), a division of the College, and covers all aspects of inflammatory disease. The American College of Rheumatology (www.rheumatology.org) is the professional organization who share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. For details, please visit onlinelibrary.wiley.com/journal/10.1002/(ISSN)1529-0131.
About Wiley-Blackwell -Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world's most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.
Related Rheumatoid Arthritis Documents
Full List of Rheumatoid Arthritis Publications Full List of Disabled World News Updates
Recent Disability News and Updates
Full List of Disabled World News Updates
Disclaimer: Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Please report outdated or inaccurate information to us.
Disclosure: Disabled World is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information.